Advagene Biopharma Co., Ltd.
About Advagene
Milestone
Management Team
Board of Directors
R&D PIPELINE
NEW DRUG PEPLINE
Intranasal Vaccines
Airway allergy immunotherapy
Covid-19-immunitytherapy
Other vaccine applications
News
News
Press Releases
Partnerships and Collaborators
Investors
Catalogs
公開資訊觀測站
繁體中文
English
简体中文
Contact Us
Home
Site Map
Site Map
About Advagene
Milestone
Management Team
Board of Directors
R&D PIPELINE
NEW DRUG PEPLINE
Intranasal Vaccines
Airway allergy immunotherapy
Covid-19-immunitytherapy
Other vaccine applications
News
News
Receives TFDA approval to conduct phase II clinical trial of AD17002 for the treatment of moderate-to-severe eosinophilic asthma.
Submits IND application to TFDA for phase II clinical trial of AD17002 in the treatment of moderate-to-severe eosinophilic asthma.
Submits interim analysis report of AD17002 nasal spray for asthma treatment to TFDA and announces early termination of the clinical trial.
The results of the Phase 2a clinical trial of the nasal spray COVID-19 immunotherapy drug AD17002 were published in the journal Human Vaccines & Immunotherapeutics. The study demonstrates that AD17002 shows good safety and tolerability in patients wit
Advagene has been invited to participate in the Host Directed Therapeutics Industry Day and the JPEO CBRND, and has been selected to deliver a verbal presentation to U.S. Government representatives.
公告本公司董事會決議現金增資發行新股案
本公司受邀參加福邦證券及環球生技月刊舉辦之「生醫產業趨勢暨企業投資論壇」
本公司鼻噴新藥AD17002治療氣喘臨床二期試驗案收受首位受試者
Results of the phase IIa human clinical trial of the new drug AD17002-SC for the treatment of COVID-19 showed good safety, tolerability, and the efficacy in virus clearance.
Obtained IND approval by TFDA to conduct phase II clinical trials of the new drug AD17002 for the treatment of patients with eosinophilic asthma.
The last subject of the Phase II clinical trial of the COVID-19 treatment in Taiwan completed the drug administration
The first subject participated in the phase II/III trial for the treatment of COVID-19 in Indonesia.
AD17002-SC for the treatment of COVID-19 was approved by BPOM to perform phase II/III human clinical trials in Indonesia.
The first subject participated in phase II human trial of new drug AD17002-SC for COVID-19.
A memorandum of Understanding (MOU) with Macter International Limited in Pakistan for the authorization and distribution of the new drug AD17002-SC for COVID-19.
New drug AD17002-SC for the treatment of COVID-19 was approved by TFDA to perform phase II human clinical trials.
Apply to TFDA for IND of AD17002-SC for the treatment of phase II human clinical trials in patients with mild COVID-19.
Apply to TFDA for Clinical Trial (IIT) to use AD17002 for the treatment of asthma caused by rhinovirus.
The results of animal challenge experiments show that the COVID-19 immunotherapy drug AD17002-SC can significantly reduce the lung inflammation caused by moderate to severe virus infections.
Cooperated with Taipei Medical University(TMU) to implement the research project "the mechanism of action of AD17002-AI application in asthma and allergic rhinitis."
The research and development project "nasal spray influenza vaccine (106IDX10023)" was selected as a potential product by TFDA.
Advagene obtained the technology authorization from National Institutes of Health(NIH), to use influenza virus particle platform to develop SARS-Cov-2 antigen. This antigen technology will be used for the development of the second-generation nasal spray C
Nasal spray new drug AD17002-AI applied to allergic rhinitis treatment in phase Ib/IIa human trial has been completed. The CSR(clinical study report) will be released in December.
Application of new drug AD17002-SC to COVID-19 immunotherapy was selected as a capstone project by CDE.
The first subject participated in cohort 3(high-dose group) of Ib/IIa trial of allergic rhinitis immunotherapy.
The safety data of cohort 2 of allergic rhinitis immunotherapy trial passed SRT(Safety review team) reviewing and got permission to enter cohort 3.
The cohort 2 trial of allergic rhinitis immunotherapy has been completed.
Polysaccharide Conjugation with LTh(αΚ) used as Vaccine obtained US patent.
The phase II clinical trial of LT-Flu nasal Flu vaccine has been published in the Vaccine Journal(https://www.ncbi.nlm.nih.gov/pubmed/31812463)
The expert committee of SRT(Safety review team) reviewed the safety data of AD17002-AI used in cohort 1(low-dose group) of allergic rhinitis immunotherapy trial and agreed to move on to the next stage of the middle-dose group.
Cohort 1 of the Ib/IIa trial of allergic rhinitis immunotherapy has been finished, including 8 weeks of follow-up inspection in the clinical trial center.
The first subject participated in cohort 1(low-dose group) of the Ib/IIa trial of allergic rhinitis immunotherapy, which is planned to recruit 16 subjects in this stage.
Initiated the Ib/IIa clinical trial of house dust mite allergy nasal spray treatment, and completed the preparation for the first visit of the clinical trial (SIV) in Taipei Medical University Hospital.
The results of the Phase II clinical trial of nasal spray influenza vaccine showed that AD07030 has no safety and tolerability concerns, and can enhance both serum and mucosal immune responses, which is in line with the purpose of the trial plan.
Obtained the IND approval from the Food and Drug Administration (TFDA) of the Ministry of Health and Welfare in Taiwan "A randomized, placebo-controlled trial to evaluate the safety, tolerability and potential efficacy of intranasal administration on
Submit the Ib/IIa clinical trial of LTh(αΚ) for the treatment of allergic rhinitis caused by house dust mite to Taiwan Food and Drug Administration (TFDA)
Complete batch production(GMP) of AD17002-AI used in the project of house-dust mite nasal spray allergy treatment Ib/IIa clinical trial.
Press Releases
【環球生技月刊】昱厚氣喘新藥獲TFDA核准執行臨床二期試驗
【環球生技月刊】昱厚鼻噴氣喘新藥 向TFDA正式遞交臨床二期試驗申請
【財訊快報】昱厚生技AD17002鼻噴新藥，預計10家醫療中心啟動正式二期臨床
【鉅亨網】昱厚AD17002鼻噴新藥 正式啟動臨床二期
【MoneyDJ】昱厚嚴重氣喘鼻噴新藥探索性二期臨床數據達標
【工商時報】昱厚嚴重氣喘鼻噴新藥 探索性二期臨床數據達標
【環球生技月刊】昱厚鼻噴新冠免疫治療藥臨床二a期試驗 加速清病毒、縮短病程登國際期刊
【經濟日報】昱厚鼻噴新冠免疫治療藥臨床二a期成果登國際期刊
【經濟日報C4】昱厚叩關美國市場 邁步
【財訊快報】自有技術平台獲國際肯定，昱厚生技獲邀向美國政府代表進行專案報告
【經濟日報】昱厚嚴重氣喘鼻噴新藥二期臨床順利 目標年底完成收案
【工商時報】昱厚嚴重氣喘鼻噴新藥二期臨床 拚年底完成收案
【環球生技月刊】美HHS擲5億美元 加速鼻噴/口服新冠疫苗臨床2期
【工商時報A14】昱厚 擬募資2.4億
【經濟日報】昱厚股東會／鼻噴新藥 AD17002積極拓展國際合作
Advagene plans to increase cash capital by 240 million to develops new drugs.
Accelerating clinical trials of new drugs, Advagene plans to increase the current limit of 8 million shares
Advagene plans to increase the current limit of 8 million shares to accelerate the clinical trials of new drugs
【鉅亨網】台灣生技業進入第三波浪潮 谷月涵看好4大類60家潛力公司出線
【經濟日報B2】興櫃一周回顧／昱厚生技勁揚四成 居冠
【工商時報B4】鼻噴新藥夯 昱厚：洽談授權中
【鉅亨網】昱厚治療新冠新藥臨床二a數據優越 獲美國BARDA邀請會議
【工商時報】新冠、氣喘病患福音？昱厚獨特治療機制報捷
【環球生技月刊】挾創新劑型、營運模式！ 昱厚、泰宗、瑩碩2024展關鍵成果
【環球生技月刊Vol. 114】昱厚徐悠深 全球創新「鼻噴蛋白藥」破風手
呼吸道治療、醫美最具商機
【工商時報A5】藥械合一夯 台廠拚打國際盃
莫德納、輝瑞新冠疫苗銷售大減！ 漲價抵衝擊還能撐多久？
【環球生技月刊】林口長庚邱政洵：防範未來大流行 亟需新立產學研發計畫、病原表型研究
【環球生技月刊】林口長庚邱政洵：臺灣新冠鼻噴藥臨床二期展療效 病毒流感化成上呼吸道防禦契機！
【MoneyDJ】昱厚生技鼻噴新冠藥二a期臨床解盲 有效縮短病程
【環球生技月刊】次世代疫苗劑型受看好！ 鼻噴、微針貼片新冠疫苗 昱厚、怡定興全力研發中
【環球生技月刊】《Cell》首證新冠病毒穿透鼻腔細胞機制！ 鼻噴藥物可望成解方
【信傳媒】不只新藥獨占鰲頭 從試劑、疫苗到細胞治療 精準健康成生技業新趨勢
【環球生技月刊】疫情漸退商機未減！ 昱厚、安特羅續拚新冠、流感臨床進度
【經濟日報】昱厚鼻噴新冠藥二/三期臨床收治首位病患 明年第2季完成收案
【中天新聞網】看好印尼市場！昱厚鼻噴新冠藥二/三期臨床在印尼收治首位病患 預估明年Q2完成收案
【工商時報】藥廠年底取證 拚史上新高
【HEHO】終於不用再挨針！各國搶研發COVID-19「鼻噴劑疫苗」國產進展一次看
【自由時報】國產噴霧型疫苗年底申請臨床試驗 羅一鈞：樂見有好成果
【中天新聞網】新冠噴霧型疫苗正夯 昱厚「接觸確診者後預防」鼻噴藥 年底前提二／三期臨床
【環球生技月刊】新冠噴霧型疫苗上陣！昱厚「接觸確診者後預防」鼻噴藥 今年內提二/三期臨床
【工商時報B4】昱厚鼻噴新冠藥 獲印尼核准臨床
【經濟日報C5】昱厚新冠藥臨床 印尼准了
【環球生技月刊】CNN：次世代新冠鼻噴「黏膜疫苗」成加強劑強力候選
【環球生技月刊】國內首個粘膜免疫預防噴劑，臨床試驗收試健康者年底上路，中斷疫情循環，上呼吸道保護噴劑預防大勢所趨
【時報資訊】昱厚鼻噴新冠治療藥克服難關 收治首位病患
【經濟日報】昱厚鼻噴新冠治療藥收首位病患 啟動IIa期臨床試驗
【環球生技月刊】台廠昱厚鼻噴劑、合一siRNA力拼新冠廣效、預防性投藥
【環球生技月刊】鎖定輕症！昱厚鼻噴新冠藥 申請食藥署IIa期人體臨床試驗
【工商時報B6】昱厚新冠新藥 擬進軍中東
【經濟日報C6】昱厚攻新冠藥 插旗巴基斯坦市場
【蘋果日報】昱厚鼻噴新冠新藥與巴基斯坦合作 進軍中東市場
【經濟日報C5】昱厚雙引擎 推升營運
【MoneyDJ】昱厚生技力推三大主力產品 加速臨床進程與商務發展
【環球生技月刊】昱厚新冠鼻噴藥AD17002-SC 獲食藥署核准進IIa期臨床試驗
【經濟日報C5】昱厚鼻噴新冠藥 准臨床試驗
【財訊快報】首個台灣鼻噴新冠藥，昱厚獲准執行IIa臨床試驗，拼Q4完成收案
【Ettoday】昱厚新冠新藥獲准執行IIa期臨床 開始收治輕症患者
【蘋果日報】對抗高變異新冠肺炎 台灣生技廠研發次世代疫
【經濟日報】昱厚報捷 有機會成為國內第一個黏膜免疫新冠疫苗
【環球生技】疫情下的產業火線-專訪昱厚生技總經理
【經濟日報A3】疫情升溫 三生技族商機大
【工商時報A4】台廠搶搭新冠解藥商機 高端、心悅、台微體、昱厚動起來
【經濟日報C5】昱厚新冠藥申請二期臨床
【鉅亨網】鼻噴劑有望成為新式新冠藥物 台微體、昱厚已進臨床
【經濟日報】昱厚鼻噴新冠藥物 已向食藥署申請二期a人體臨床試驗
【工商時報】昱厚鼻噴新冠藥AD17002-SC 申請台灣TFDA二期臨床
【經濟日報C5】昱厚鼻噴藥 搶抗疫商機
【財訊快報】昱厚生技新藥AD17002，申請鼻病毒引起之氣喘二期臨床試驗
【經濟日報C6】昱厚新藥 申請二期臨床
【經濟日報】國光生公費流感疫苗訂單到手 將積極展開國際化布局
【經濟日報C6】昱厚鼻噴疫苗 拚打世界盃
【工商時報】接種疲乏效應 國產疫苗有望打世界盃
【經濟日報C5】昱厚抗疫藥 拚二期臨床
【工商時報B6】昱厚新冠藥物 傳喜訊
【鏡週刊】老牌半導體廠投資生技有成 昱厚搶新冠黏膜新藥商機
【鉅亨網】昱厚鼻噴型新冠藥物 最快3月底申請人體臨床試驗
【環球生技月刊】刺激「先天免疫」新冠肺炎抗疫最有效 昱厚鼻噴藥AD19001預防、輕症治療 動物試驗成效佳
【財訊快報】昱厚攻新冠雙管齊下 噴鼻劑型疫苗拚明年上半年進臨床試驗
【MoneyDJ】昱厚生技四大產品線各擁利基 布局新冠疫苗/治療藥物
【環球生技月刊】昱厚過敏療法Ib/IIa期臨床成績突出、鼻噴新冠疫苗明年Q2申請IND
【經濟日報】昱厚過敏性鼻炎新藥完成Ib/IIa臨床 股價走強
【環球生技月刊】昱厚過敏性鼻炎藥 Ib/IIa期試驗結果：安全性佳、症狀改善過半數
【公告】公告本公司研發新藥AD17002[LTh(αΚ)]屋塵蹣過敏性 鼻炎治療臨床Ib/IIa期試驗結果
【公告】公告本公司「噴鼻流感佐劑疫苗(106IDX10023)」研發案件 ，獲衛福部食藥署(TFDA)評選列入諮詢輔導案件
【公告】昱厚生技委託臺北醫學大學執行「LTh(αk)應用於氣喘與過敏性鼻炎免疫調控機轉研究計畫」之產學合作
【經濟日報】昱厚 將開發新冠疫苗
【環球生技月刊】昱厚取國衛院抗原技術授權 開發鼻噴新冠疫苗 股價漲4%
【必富網】昱厚LTh(αK)技術 疫苗創新研發助力
【經濟日報】昱厚搭上新冠順風車 股價衝38.55元、漲幅最高達20%
【經濟日報】用噴的更有效？台灣鼻噴新冠藥進展大突破
【環球生技月刊】疫苗國家隊最沈默的黑馬！ 昱厚LTh(αK)蛋白「鼻噴」藥物、疫苗挺進II期、I期
【工商時報】昱厚 申請COVID-19粘膜免疫治療專利
【國衛院電子報】國衛院論壇「台灣新冠肺炎COVID-19疫苗緊急開發策略」專家諮詢會議
【健康醫療網】這家台灣公司疫苗佐劑已Ready 有望加速武漢肺炎疫苗研發
【中時/工商時報】昱厚噴鼻疫苗研究成果 獲國際疫苗期刊登載
【生策會】發佈關於昱厚解盲及刊登國際期刊訊息
噴鼻流感疫苗臨床一期結果已發表在Vaccine期刊
【聯合/經濟日報】興櫃新星 昱厚新藥臨床 邁大步
【發現新台灣】昱厚生技噴鼻流感疫苗
【中時】昱厚生技 噴鼻流感疫苗二期臨床試驗結果超乎預期
【DJ新視界】昱厚噴鼻疫苗之佐劑 可加速療效
Partnerships and Collaborators
Investors
Catalogs
公開資訊觀測站
繁體中文
English
简体中文
